ReviewCurrent heart failure reports2018
Gene Therapy for Heart Failure: New Perspectives.
Review in Current heart failure reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model.Communications medicine · 2025Article
- A review on regulation of DNA methylation during post-myocardial infarction.Frontiers in pharmacology · 2024Review
- Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction.International journal of molecular sciences · 2023Review
- Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes.Molecular therapy. Methods & clinical development · 2023Article
- Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases.Advances in experimental medicine and biology · 2023Article
- Genome Editing and Cardiac Regeneration.Advances in experimental medicine and biology · 2023Article
- Gene Therapy With the N-Terminus of Junctophilin-2 Improves Heart Failure in Mice.Circulation research · 2022Article
- Genomic enhancers in cardiac development and disease.Nature reviews. Cardiology · 2022Review
- Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity:JACC. CardioOncology · 2021Review
- Upregulation of miR-128 Mediates Heart Injury by Activating Wnt/β-catenin Signaling Pathway in Heart Failure Mice.Organogenesis · 2021Article
- Lipidomics Revealed Alteration of Sphingolipid Metabolism During the Reparative Phase After Myocardial Infarction Injury.Frontiers in physiology · 2021Article
- The protective effects of the miR-129-5p/keap-1/Nrf2 axis on Ang II-induced cardiomyocyte hypertrophy.Annals of translational medicine · 2021Article
- Comparative analysis of adeno-associated virus serotypes for gene transfer in organotypic heart slices.Journal of translational medicine · 2020Article
- Mitochondrial CaActa pharmacologica Sinica · 2020Review
- Hydrogel-Based Localized Nonviral Gene Delivery in Regenerative Medicine Approaches-An Overview.Pharmaceutics · 2020Review
- Calcium Signaling in Cardiomyocyte Function.Cold Spring Harbor perspectives in biology · 2020Review
- Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine.Circulation research · 2019Review
- Update on heart failure management and future directions.The Korean journal of internal medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe current knowledge of pathophysiological and molecular mechanisms responsible for the genesis and development of heart failure (HF) is absolutely vast. Nonetheless, the hiatus between experimental findings and therapeutic options remains too deep, while the available pharmacological treatments are mostly seasoned and display limited efficacy. The necessity to identify new, non-pharmacological strategies to target molecular alterations led investigators, already many years ago, to propose gene therapy for HF. Here, we will review some of the strategies proposed over the past years to target major pathogenic mechanisms/factors responsible for severe cardiac injury developing into HF and will provide arguments in favor of the necessity to keep alive research on this topic. RECENT
findingsAfter decades of preclinical research and phases of enthusiasm and disappointment, clinical trials were finally launched in recent years. The first one to reach phase II and testing gene delivery of sarcoendoplasmic reticulum calcium ATPase did not yield encouraging results; however, other trials are ongoing, more efficient viral vectors are being developed, and promising new potential targets have been identified. For instance, recent research is focused on gene repair, in vivo, to treat heritable forms of HF, while strong experimental evidence indicates that specific microRNAs can be delivered to post-ischemic hearts to induce regeneration, a result that was previously thought possible only by using stem cell therapy. Gene therapy for HF is aging, but exciting perspectives are still very open.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.